Cohance Lifesciences Limited (SUVENPHAR.NS)
- Previous Close
1,079.10 - Open
1,077.00 - Bid --
- Ask --
- Day's Range
1,046.80 - 1,088.00 - 52 Week Range
598.00 - 1,360.00 - Volume
202,810 - Avg. Volume
385,732 - Market Cap (intraday)
404.832B - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
97.08 - EPS (TTM)
10.90 - Earnings Date May 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 9, 2022
- 1y Target Est
1,396.67
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is based in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
www.cohance.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUVENPHAR.NS
View MorePerformance Overview: SUVENPHAR.NS
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUVENPHAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUVENPHAR.NS
View MoreValuation Measures
Market Cap
412.56B
Enterprise Value
406.23B
Trailing P/E
98.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.69
Price/Book (mrq)
20.87
Enterprise Value/Revenue
39.33
Enterprise Value/EBITDA
92.34
Financial Highlights
Profitability and Income Statement
Profit Margin
26.63%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
10.48B
Net Income Avi to Common (ttm)
2.79B
Diluted EPS (ttm)
10.90
Balance Sheet and Cash Flow
Total Cash (mrq)
6.56B
Total Debt/Equity (mrq)
1.95%
Levered Free Cash Flow (ttm)
--